Subject: Specialty Quantity Limit Tivdak 4986-H P2023

Drug

TIVDAK  (tisotumab vedotin-tftv)

Policy:

I.  PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.


II.  COVERED QUANTITIES|

Medication	Standard        Limit	FDA-recommended dosing
Tivdak   (tisotumab vedotin-tftv)   40 mg single-dose vial for   reconstitution	5 vials (200 mg)   per 21 days	2 mg/kg (up to a maximum of 200 mg for patients >          100 kg) IV over 30 minutes every 3 weeks   Dose modifications may be needed for adverse reactions.

 

Place of Service:

Outpatient

The above policy is based on the following references:

1. Tivdak [package insert]. Bothell, WA: Seagen Inc.; July 2023.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

December 31, 2023